IC
ACAD icon

IEQ Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

IEQ Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$596K Sell
26,789
-55,555
-67% -$1.33M ﹤0.01% 1230
2025
Q4 		$2.2M Buy
82,344
+8,865
+12% +$212K 0.01% 759
2025
Q3 		$1.57M Buy
73,479
+26,061
+55% +$616K ﹤0.01% 845
2025
Q2 		$1.02M Buy
+47,418
New +$881K 0.01% 851

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

IEQ Capital's ACAD Position: Q1 2026 in Review

IEQ Capital reduced its Acadia Pharmaceuticals (ACAD) stake by 67% in Q1 2026, selling an estimated $1.33M and leaving 26,789 shares worth $596K. The position accounts for ﹤0.01% of the portfolio, ranked #1230.

IEQ Capital first reported a position in ACAD in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.2M in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • IEQ Capital held 26,789 shares of Acadia Pharmaceuticals worth $596K as of Q1 2026.
  • IEQ Capital sold 55,555 Acadia Pharmaceuticals shares in Q1 2026, an estimated $1.33M.
  • Acadia Pharmaceuticals made up ﹤0.01% of IEQ Capital's portfolio in Q1 2026, its #1230 holding.
  • IEQ Capital first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • IEQ Capital's Acadia Pharmaceuticals position peaked at $2.2M in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.